<span item_type="fundamental" item_id="d44fb75e604520f67ba63d1c3f2ec67d" counter_id="ST/US/BCTX" env="prod"></span><span item_type="announcement" item_id="592581970748247041" env="prod"></span><p>Revenue: As of FY2026 Q1, the actual value is USD 0.</p><p>EPS: As of FY2026 Q1, the actual value is USD -4.35.</p><p>EBIT: As of FY2026 Q1, the actual value is USD -8.371 M.</p><p></p><h3>Operating Expenses</h3><ul><li><strong>Research and Development Expenses</strong>: $6,683,643 for the three months ended October 31, 2025, compared to $3,665,341 for the same period in 2024, primarily due to increased clinical trial sites and investigational drug costs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1610820/000149315225027240/form10-q.htm"></span></li><li><strong>General and Administrative Expenses</strong>: $1,639,300 for the three months ended October 31, 2025, compared to $1,487,491 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1610820/000149315225027240/form10-q.htm"></span></li></ul><h3>Operating Loss</h3><ul><li><strong>Operating Loss</strong>: - $8,322,943 for the three months ended October 31, 2025, compared to - $5,152,832 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1610820/000149315225027240/form10-q.htm"></span></li></ul><h3>Net Loss</h3><ul><li><strong>Net Loss</strong>: - $8,278,328 for the three months ended October 31, 2025, compared to - $5,829,276 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1610820/000149315225027240/form10-q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: - $7,704,796 for the three months ended October 31, 2025, compared to - $6,955,076 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1610820/000149315225027240/form10-q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company is advancing its Bria-IMT™ targeted immunotherapy in a pivotal Phase 3 study in metastatic breast cancer, with top-line data expected in the first half of 2026. The company is also developing Bria-OTS™ as a platform technology for personalized off-the-shelf immunotherapies for various cancers.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1610820/000149315225027240/form10-q.htm"></span></li><li><strong>Non-Core Business</strong>: The company is exploring additional sources of capital and financing to support its operations and has been awarded a $2.0 million SBIR grant from the U.S. National Cancer Institute to advance Bria-PROS+™ in prostate cancer.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1610820/000149315225027240/form10-q.htm"></span></li></ul>

BriaCell Therapeutics | 10-Q: FY2026 Q1 Revenue: USD 0